Plain-English fact sheet
Ziconotide
Also known as Prialt, SNX-111
Ziconotide is an FDA-approved non-opioid peptide for severe chronic pain when intrathecal therapy is warranted, but it carries major psychiatric and neurologic risks.
Quick answer
Ziconotide is FDA approved as Prialt for severe chronic pain in people who need intrathecal therapy and cannot tolerate or do not respond to other treatment. It is not a routine pain supplement and has a boxed warning for severe psychiatric and neurologic effects.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Ziconotide?
Ziconotide is a synthetic version of a 25-amino-acid conopeptide originally identified in cone-snail venom.
It blocks N-type calcium channels involved in pain signaling and is delivered into the fluid around the spinal cord through specialist equipment.
Why are people interested in it?
It shows that a venom-derived peptide can become a non-opioid medicine for otherwise difficult pain.
Its narrow delivery setting and serious central nervous system effects are as important as its novel mechanism.
Current regulatory status
Prialt is FDA approved for severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment.
What is it approved for?
- Management of severe chronic pain when intrathecal therapy is warranted and other treatment is ineffective or not tolerated
What is it being studied for?
Investigational areas
- Other highly selected pain settings under specialist research
Evidence snapshot
Randomized placebo-controlled trials support analgesic benefit in selected severe-pain populations. Adverse effects and the need for specialist intrathecal delivery sharply limit generalization.
Potential benefits being researched
- Controlled trials found greater average pain reduction than placebo in selected people with severe refractory pain.
- It is not an opioid and does not work through opioid receptors, which makes its mechanism clinically distinctive.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- The boxed warning describes severe psychiatric symptoms and neurologic impairment; people with a history of psychosis should not receive Prialt.
- Confusion, hallucinations, mood or consciousness changes, dizziness, gait problems, memory impairment, nausea, and other neurologic effects can occur.
- Intrathecal equipment introduces risks such as meningitis and catheter or pump complications.
What we still do not know
- Which patients can obtain durable benefit without unacceptable neurologic effects
- Long-term comparative outcomes versus other specialist pain approaches
- How trial averages translate across different causes of severe pain
Plain-English takeaway
Ziconotide is a striking peptide success story, but not a casual one: its benefit belongs to a narrow, specialist pain setting with serious neuropsychiatric and device-related risks.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA prescribing information: Prialt
Official indication, boxed warning, safety information, and clinical-study summary.
- 2Randomized trial in severe chronic pain
Placebo-controlled study of analgesic benefit and neurologic adverse effects.
- 3Randomized trial in chronic nonmalignant pain
Controlled trial illustrating both pain reduction and substantial adverse effects with faster escalation.